Taste, pain, or response to stress—nearly all essential functions in the human body are regulated by molecular switches ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

G protein-coupled receptors are embedded in the cell membrane and transmit signals from the outside to the inside of the cell. Because of their vast diversity and crucial role in the body, GPCRs ...

Researchers used GPS-like tracking to observe how a key G protein-coupled receptor (GPCR) moves, revealing the core mechanism behind vital body functions. G protein-coupled receptors are embedded in ...

Taste, pain, or response to stress — nearly all essential functions in the human body are regulated by molecular switches called G protein-coupled receptors (GPCRs). Researchers at the ...